Suppr超能文献

高收入环境下围产期健康干预措施的成本效益及获益:一项系统评价中经济评估的方案。

Cost-effectiveness and benefits of perinatal health interventions in high-income settings: A protocol for a systematic review of economic evaluations.

机构信息

Curtin School of Population Health, Curtin University, Perth, WA, Australia.

Department of Health Systems and Policy, Institute of Public Health, University of Gondar, Gondar, Ethiopia.

出版信息

PLoS One. 2024 Jul 2;19(7):e0306557. doi: 10.1371/journal.pone.0306557. eCollection 2024.

Abstract

BACKGROUND

Despite ongoing efforts, perinatal morbidity and mortality persist across all settings, imposing a dual burden of clinical and economic strain. Besides, the fragmented nature of economic evidence on perinatal health interventions hinders the formulation of effective health policies. Our review aims to comprehensively and critically assess the economic evidence for such interventions in high-income countries, where the balance of health outcomes and fiscal prudence is paramount.

METHODS AND ANALYSIS

We will conduct a comprehensive search for studies using databases including EconLit (EBSCO), Cost Effectiveness Analysis (CEA) Registry, Medline (Ovid), Embase (Ovid), CINAHL Ultimate (EBSCO), Global Health (Ovid), and PubMed. Furthermore, we will broaden our search to include Google Scholar and conduct snowballing from the final articles included. The search terms will encompass economic evaluation, perinatal health interventions, morbidity and mortality, and high-income countries. We will include full economic evaluations focusing on cost-effectiveness, cost-benefit, cost-utility, and cost-minimisation analyses. We will exclude partial economic evaluations, reports, qualitative studies, conference papers, editorials, and systematic reviews. Date restrictions will limit the review to studies published after 2010 and those in English during the study selection process. We will use the modified Drummond checklist to evaluate the quality of each included study. Our findings will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement. A summary will include estimated costs, effectiveness, benefits, and the incremental cost-effectiveness ratio (ICER). We also plan to conduct a subgroup analysis. To aid comparability, we will standardise all costs to the United States Dollar, adjusting them to their 2022 value using country-specific consumer price index and purchasing power parity.

ETHICS AND DISSEMINATION

This systematic review will not involve human participants and requires no ethical approval. We will publish the results in a peer-reviewed journal.

TRIAL REGISTRATION

We registered our record on PROSPERO (registration #: CRD42023432232).

摘要

背景

尽管一直在努力,但围产期发病率和死亡率在所有环境中仍然存在,给临床和经济带来双重负担。此外,围产期卫生干预措施的经济证据分散,阻碍了有效的卫生政策的制定。我们的综述旨在全面、批判性地评估高收入国家此类干预措施的经济证据,在这些国家,健康结果和财政谨慎之间的平衡至关重要。

方法和分析

我们将使用包括 EconLit(EBSCO)、成本效果分析(CEA)登记处、Medline(Ovid)、Embase(Ovid)、CINAHL 终极版(EBSCO)、全球健康(Ovid)和 PubMed 在内的数据库,全面搜索研究。此外,我们将扩大搜索范围,包括 Google Scholar,并从最终纳入的文章进行滚雪球式搜索。搜索词将包括经济评价、围产期卫生干预措施、发病率和死亡率以及高收入国家。我们将纳入重点关注成本效益、成本效益、成本效用和成本最小化分析的全经济评价。我们将排除部分经济评价、报告、定性研究、会议论文、社论和系统评价。日期限制将使本综述仅限于 2010 年后发表的研究,以及研究选择过程中发表的英语研究。我们将使用改良的 Drummond 清单评估每项纳入研究的质量。我们的研究结果将遵循系统评价和荟萃分析的首选报告项目(PRISMA)2020 声明。总结将包括估计成本、效果、效益和增量成本效果比(ICER)。我们还计划进行亚组分析。为了便于比较,我们将所有成本标准化为美元,使用特定国家的消费者价格指数和购买力平价将其调整为 2022 年的价值。

伦理和传播

本系统评价不涉及人类参与者,不需要伦理批准。我们将在同行评议的期刊上发表结果。

试验注册

我们在 PROSPERO(注册号:CRD42023432232)上注册了我们的记录。

相似文献

4
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Cost of maternal health services in low and middle-income countries: protocol for a systematic review.
BMJ Open. 2019 Aug 20;9(8):e027822. doi: 10.1136/bmjopen-2018-027822.

本文引用的文献

2
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Int J Surg. 2021 Apr;88:105906. doi: 10.1016/j.ijsu.2021.105906. Epub 2021 Mar 29.
3
Global burden of preterm birth.
Int J Gynaecol Obstet. 2020 Jul;150(1):31-33. doi: 10.1002/ijgo.13195.
4
Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation.
BMC Med Res Methodol. 2020 Jan 13;20(1):7. doi: 10.1186/s12874-020-0897-3.
5
What are the costs of stillbirth? Capturing the direct health care and macroeconomic costs in Australia.
Birth. 2020 Jun;47(2):183-190. doi: 10.1111/birt.12469. Epub 2019 Nov 18.
6
The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
Am J Obstet Gynecol. 2017 Mar;216(3):B11-B13. doi: 10.1016/j.ajog.2017.01.022. Epub 2017 Jan 23.
7
Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF).
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:217-224. doi: 10.1016/j.ejogrb.2016.12.035. Epub 2016 Dec 30.
8
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.
Am J Obstet Gynecol. 2017 Feb;216(2):121-128.e2. doi: 10.1016/j.ajog.2016.10.016. Epub 2016 Nov 1.
9
Stillbirths: economic and psychosocial consequences.
Lancet. 2016 Feb 6;387(10018):604-616. doi: 10.1016/S0140-6736(15)00836-3. Epub 2016 Jan 19.
10
Exploring the intangible economic costs of stillbirth.
BMC Pregnancy Childbirth. 2015 Sep 1;15:188. doi: 10.1186/s12884-015-0617-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验